CDT stock forecast, quote, news & analysis

Key Takeaways

• CDT shares fell roughly 93% over the trailing 30 days, sliding from about $0.99 at the start of October to about $0.07 by early November.
• The move extends a far deeper collapse: the stock traded near $71 in early August, leaving the three-month decline near 99.9%.
• Severe share dilution was the central driver, after pre-funded warrants covering roughly 12.1 million shares were exercised in late August 2026.
• CDT reports no product revenue and has flagged substantial doubt about its ability to continue as a going concern.
• A series of reverse stock splits has been used to maintain Nasdaq listing compliance as the share price deteriorated.
• For additional details, explore CDT's Price Targets, Earnings, and Forecast pages.
• Discover top-performing automated strategies on the Trending AI Robots page.

CDT Equity (CDT) Company Overview and Market Position

CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a data-driven biopharmaceutical company based in Naples, Florida. It focuses on identifying, enhancing, and monetizing therapeutic assets, using artificial intelligence, solid-form chemistry and co-crystallization, and asset repositioning rather than running late-stage clinical trials itself. Its pipeline, licensed from AstraZeneca, includes AZD1656 (a glucokinase activator in Phase II for autoimmune disorders), AZD5658 (Phase I for Type 2 diabetes), and AZD5904 (completed Phase I for idiopathic male infertility), alongside earlier programs in dermatology and animal health. Investors follow CDT largely for its repositioning strategy and its push into AI-driven drug discovery through its stake in Sarborg Limited, a private "agentic AI" venture.

CDT Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CDT fell roughly 93%, from a closing price near $0.99 in early October to about $0.07 by early November. The decline has been persistent rather than a single-event gap, with the stock losing ground through much of the month amid heavy trading volume.

The quarterly picture is even starker. In early August, CDT traded near $71; the subsequent three-month move represents a decline of roughly 99.9%. The collapse accelerated in September, when a "capital update" and the full effect of a large warrant exercise became apparent to the market.

What Drove CDT Stock Price in the Last 30 Days

The most important factor has been dilution. In July 2026, CDT agreed to issue pre-funded warrants covering approximately 12.13 million shares at a nominal exercise price of $0.0001 to acquire a stake in Sarborg Limited. When holders exercised those warrants on a cashless basis in late August, the company issued roughly 12.13 million new common shares — close to nine of every ten shares then outstanding. The resulting overhang and continued selling pressure weighed heavily on the stock through October.

Fundamental concerns compounded the move. CDT generates no product revenue and has disclosed substantial doubt about its ability to continue as a going concern, while reporting steady net losses. Against that backdrop, the stock's drift toward penny-stock levels reflected waning confidence in the company's ability to convert its illiquid Sarborg stake and pipeline into tangible value.

What Drove CDT Stock Performance Over the Last Quarter

The quarterly collapse traces back to the company's September "capital update," which framed a large share issuance as reassuring news while markets read it as dilution. Shares fell in the regular session and dropped further after hours as investors digested the scale of the new share count. The company has also used a series of reverse stock splits — including a 1-for-10 reverse split effective in July 2026 — to prop up the share price and maintain Nasdaq listing compliance, a pattern that itself signals ongoing stress. Combined with no product revenue and going-concern disclosures, these factors produced the extended decline.

Trending AI Robots

Tickeron's Trending AI Robots page curates the top-performing and most relevant automated trading strategies from a broader universe of hundreds of AI trading bots covering thousands of tickers. Only the most notable bots appear in this section, and each differs in strategy, timeframe, and performance metrics, so the page offers a way to compare approaches rather than a single one-size-fits-all signal. Traders interested in systematic, rules-based tools can browse the curated list to see which Trending AI Robots are currently standing out.

CDT Stock Forecast Drivers: What Investors Should Watch Next

Several factors will shape CDT's path. First, watch any additional capital raises or share issuances, including use of the company's at-the-market offering program, which could further dilute existing holders. Second, monitor whether the Sarborg Limited stake is converted into tangible value or remains an illiquid mark on the balance sheet. Third, track the progression of the AZD1656, AZD5658, and AZD5904 programs and any licensing or partnership agreements, including the recent evaluation agreement with Manoira in animal health. Finally, watch Nasdaq listing compliance and the company's ability to resolve its going-concern disclosure. None of this constitutes financial advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations